top of page
  • Writer's pictureKanna Health

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

LONDON, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have approved Kanna Health's Investigational New Drug (IND) application and Clinical Trial Application (CTA), respectively, to start participant enrollment in a Phase 1 first-in-human clinical trial investigating the Safety and Pharmacokinetics of KH-001 Besylate (KH-001) in Healthy Male Subjects.

KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation. These regulatory approvals signify a potential breakthrough in the management of a widespread condition, impacting up to 20% of men and their partners worldwide.

The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO).

Dr Ryan Protzko, Kanna Health's President, stated:

"Our clinical trial approval on both sides of the Atlantic represents a critical milestone as we officially become a clinical stage company. The study marks the start of a journey towards understanding the therapeutic potential of KH-001 in humans, in cooperation with regulatory bodies in our priority markets."

"This approval allows Kanna Health to advance our understanding of how KH-001 may provide patients with a potentially transformative therapy, where no drug treatments are approved in the US and few treatment options exist worldwide", said Dr Hans-Juergen Gruss, Kanna Health's Chief Medical Officer.

About Premature Ejaculation

Premature ejaculation is the most common form of male sexual dysfunction, impacting ~20% of men (Shindel AW, Althof SE, Carrier S et al.: Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol 2022), with its most severe form characterized by ejaculation within 1 minute of penetration (~3% of men). Premature ejaculation is associated with secondary psychological effects, with 65% of patients reporting personal distress as a result including anxiety, depression, low self-esteem, and a negative impact on relationships.

About Kanna Health Ltd

Kanna Health is a clinical-stage biopharmaceutical company developing novel fast-acting small molecule therapeutics for sexual and mental health conditions.

Further information:

For further information, please contact John Boghossian (email:

SOURCE Kanna Health Ltd


bottom of page